Literature DB >> 11937567

Regulation of the mannan-binding lectin pathway of complement on Neisseria gonorrhoeae by C1-inhibitor and alpha 2-macroglobulin.

Sunita Gulati1, Kedarnath Sastry, Jens C Jensenius, Peter A Rice, Sanjay Ram.   

Abstract

We examined complement activation by Neisseria gonorrhoeae via the mannan-binding lectin (MBL) pathway in normal human serum. Maximal binding of MBL complexed with MBL-associated serine proteases (MASPs) to N. gonorrhoeae was achieved at a concentration of 0.3 microg/ml. Preopsonization with MBL-MASP at concentrations as low as 0.03 microg/ml resulted in approximately 60% killing of otherwise fully serum-resistant gonococci. However, MBL-depleted serum (MBLdS) reconstituted with MBL-MASP before incubation with organisms (postopsonization) failed to kill at a 100-fold higher concentration. Preopsonized organisms showed a 1.5-fold increase in C4, a 2.5-fold increase in C3b, and an approximately 25-fold increase in factor Bb binding; enhanced C3b and factor Bb binding was classical pathway dependent. Preopsonization of bacteria with a mixture of pure C1-inhibitor and/or alpha(2)-macroglobulin added together with MBL-MASP, all at physiologic concentrations before adding MBLdS, totally reversed killing in 10% reconstituted serum. Reconstitution of MBLdS with supraphysiologic (24 microg/ml) concentrations of MBL-MASP partially overcame the effects of inhibitors (57% killing in 10% reconstituted serum). We also examined the effect of sialylation of gonococcal lipooligosaccharide (LOS) on MBL function. Partial sialylation of LOS did not decrease MBL or C4 binding but did decrease C3b binding by 50% and resulted in 80% survival in 10% serum (lacking bacteria-specific Abs) even when sialylated organisms were preopsonized with MBL. Full sialylation of LOS abolished MBL, C4, and C3b binding, resulting in 100% survival. Our studies indicate that MBL does not participate in complement activation on N. gonorrhoeae in the presence of "complete" serum that contains C1-inhibitor and alpha(2)-macroglobulin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11937567     DOI: 10.4049/jimmunol.168.8.4078

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Alpha-2,3-sialyltransferase enhances Neisseria gonorrhoeae survival during experimental murine genital tract infection.

Authors:  Hong Wu; Ann E Jerse
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  Properdin is critical for antibody-dependent bactericidal activity against Neisseria gonorrhoeae that recruit C4b-binding protein.

Authors:  Sunita Gulati; Sarika Agarwal; Shreekant Vasudhev; Peter A Rice; Sanjay Ram
Journal:  J Immunol       Date:  2012-02-24       Impact factor: 5.422

Review 3.  Mannan-binding-lectin-associated serine proteases, characteristics and disease associations.

Authors:  Rikke Sørensen; Steffen Thiel; Jens C Jensenius
Journal:  Springer Semin Immunopathol       Date:  2005-11-11

4.  Mannose-binding lectin is present in human semen and modulates cellular adhesion of Neisseria gonorrhoeae in vitro.

Authors:  J B Wing; D L Jack; M E Lee; A A Pacey; G R Kinghorn; R C Read
Journal:  Clin Exp Immunol       Date:  2009-09       Impact factor: 4.330

5.  Gonococcal lipooligosaccharide sialylation: virulence factor and target for novel immunotherapeutics.

Authors:  Sanjay Ram; Jutamas Shaughnessy; Rosane B de Oliveira; Lisa A Lewis; Sunita Gulati; Peter A Rice
Journal:  Pathog Dis       Date:  2017-06-01       Impact factor: 3.166

Review 6.  Utilizing complement evasion strategies to design complement-based antibacterial immunotherapeutics: Lessons from the pathogenic Neisseriae.

Authors:  Sanjay Ram; Jutamas Shaughnessy; Rosane B DeOliveira; Lisa A Lewis; Sunita Gulati; Peter A Rice
Journal:  Immunobiology       Date:  2016-06-01       Impact factor: 3.144

7.  Mannan binding lectin in febrile adults: no correlation with microbial infection and complement activation.

Authors:  A N Tacx; A B J Groeneveld; M H Hart; L A Aarden; C E Hack
Journal:  J Clin Pathol       Date:  2003-12       Impact factor: 3.411

Review 8.  Be on Target: Strategies of Targeting Alternative and Lectin Pathway Components in Complement-Mediated Diseases.

Authors:  József Dobó; Andrea Kocsis; Péter Gál
Journal:  Front Immunol       Date:  2018-08-08       Impact factor: 7.561

Review 9.  Targeting Lipooligosaccharide (LOS) for a Gonococcal Vaccine.

Authors:  Sunita Gulati; Jutamas Shaughnessy; Sanjay Ram; Peter A Rice
Journal:  Front Immunol       Date:  2019-02-27       Impact factor: 7.561

10.  Species-specific differences in regulation of macrophage inflammation by the C3a-C3a receptor axis.

Authors:  Tathagat Dutta Ray; Samrawit Mekasha; Yanmei Liang; Bao Lu; Sanjay Ram; Robin R Ingalls
Journal:  Innate Immun       Date:  2018-01-03       Impact factor: 2.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.